PharmVar released changes and additions to the CYP2C19 allele definitions which includes an update of the CYP2C19*2 core allele definition. Prior to the latest release, the CYP2C19*2 allele was defined by three core variants, c.332-23A>G (splice defect), c.681G>A (splice defect) and

Register now for the upcoming PGRN/ClinPGx meeting - early bird registration ends July 27! This year's meeting is being held September 26-27 at Northwestern University in Chicago. The conference kicks off with a networking breakfast, including a ClinPGx User meeting (additional details to come), then a keynote

UPDATE 7/29/2026: Thank you to all the people who participated in the survey. We have the information we need and have closed the survey. Watch the blog for more updates about our drug categories! We would like to improve the drug categories that are used on the PharmDOG

We are excited to announce our latest release! This update is highly recommended. It fixes an issue with pharmcat_pipeline where it uses the original input VCF instead of the preprocessed VCF if it is given a directory instead of a file. Data highlights * PharmVar: new alleles were released for

Although the updated CPIC guideline for DPYD and fluoropyrimidines is still in development, the authors have concluded, based on current evidence, that c.1129-5923C>G, the minor allele at rs75017182 and causal allele associated with the “HapB3” haplotype, will be assigned an allele value of 0.75. For

A correction to Table 1 of the "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update" was published in Clinical Pharmacology and Therapeutics. An individual carrying one no function allele plus one decreased function allele is an Intermediate Metabolizer (IM)